Ariad Pharmaceuticals (ARIA) Reports Q2 Results
More News related to ARIA
- ARIAD to Present at the Piper Jaffray 20th Annual Healthcare Conference
- ARIAD to Present Preclinical Data on Multi-Targeted Kinase Inhibitor at 50th Ash Annual Meeting
- ARIAD To Present at the Lazard Capital Markets 5th Annual Healthcare Conference
- Ariad Pharmaceuticals (ARIA) Misses Q3 View; Guides
- ARIAD Reports Third Quarter 2008 Financial Results and Development Progress
Ariad Pharmaceuticals (Nasdaq: ARIA) reports Q2 loss of $0.25, 2 cents better than the analyst estimate of ($0.27). Revenues for the quarter were $1.45 million, versus the consensus of $2.75 million.
Related Categories
EarningsStocks Mentioned
-0.11Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
